Table 1 Literature included in the report

Castelnuovo

Persons who inject drugs

UK

Compared focused case-finding to background testing

Interferon

16,514£/QALY

[10]

Selvapatt

Persons who inject drugs

UK

Compared testing and treatment in a drug treatment unit to no testing and no treatment

DAA

1029£/QALY

[11]

Loubiere

Persons who inject drugs

France

Compared testing with EIA to no testing

Interferon

3825€/QALY

[12]

Leal

Persons who inject drugs

UK

Compared testing and treating PWID to no testing and no treatment

Interferon

9300£/QALY

[13]

Stein

Persons who inject drugs

UK

Compared testing and treating PWID to no testing and no treatment

Interferon

28,000£/QALY

[14]

Thompson Coon

Persons who inject drugs

UK

Compared focused case-finding to background testing

Interferon

16,000£/QALY

[15]

Schackman

Persons who inject drugs

US

Compared on-site and off-site HCV testing offer in a substance abuse treatment program to no HCV testing offer

Both

18,300$/QALY

[16]

Cipriano

Persons who inject drugs

US

Compared several different interval testing strategies for HCV and HIV compared to no testing

Interferon

168,600$/QALY

[17]

Martin^a

Persons who inject drugs

UK

Compared dried blood spot HCV testing to no testing in addiction services

Interferon

14,600£/QALY

[18]

Martin^a

People in prison

UK

Compared dried blood spot HCV testing to no testing in prison

Interferon

59,400£/QALY

[18]

Sutton

People in prison

UK

Compared testing in prison to testing only in the community

Interferon

54,852£/QALY

[19]

Martin

People in prison

UK

Compared increased case-finding in prisons to background testing

DAA

15,090£/QALY

[20]

He

People in prison

US

Compared risk-based opt-out testing in prison to no testing

DAA

29,234$/QALY

[21]

Sutton

People in prison

UK

Compared four case-finding scenarios on intake to prison to no case finding efforts

N/A

£6388/case identified

[22]

Linas

HIV-infected MSM

US

Compared interval testing to symptom-based testing

Interferon

57,800$/QALY

[23]

Nakamura

Birth cohort

Japan

Compared national testing programs to no testing, stratified by age group

Interferon

848$-4825$/QALY

[24]

Coffin

Birth cohort

US

Compared testing of individuals born between 1945 and 1965 to general population testing

Interferon

5400$/QALY

[25]

McEwan

Birth cohort

US

Compared testing of individuals born between 1945 and 1965 to risk-based testing

Interferon

28,602$/QALY

[26]

McGarry

Birth cohort

US

Compared testing of individuals born between 1946 and 1970 to risk-based testing

Both

37,700$/QALY

[27]

Rein

Birth cohort

US

Compared testing of individuals born between 1945 and 1965 to the standard of care

Both

35,700$/QALY

[28]

Liu

Birth cohort

US

Compared testing of individuals aged 40–64 to no testing

Interferon

65,749$/QALY

[29]

Wong

Birth cohort

Canada

Compared testing and treatment to no testing and no treatment in 45–64 year olds

Both

36,471$/QALY

[30]

Ruggeri^a

Birth cohort

Italy

Compared testing to no testing, stratified by age

Interferon

1383–10,432€/QALY

[31]

Ruggeri^a

General population

Italy

Compared testing to no testing

Interferon

5171€/QALY

[31]

Eckman

General population

US

Compared testing and treatment to no testing or treatment

DAA

47,276$/QALY

[32]

Deuffic-Burban

General population

France

Compared different follow-up schedules for detection of occupational HCV infection

Interferon

€2020/QALY

[33]

Miners

General population

UK

Compared elevated testing of migrants to the UK to the current background rate of testing

Interferon

£23,200/QALY

[34]

Kim

General population

Egypt

Compared testing and treatment to no testing or treatment

Both

Cost saving

[35]